We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Molecular and Clinical Insights in the Increasing Detection of BCR::ABL1 p190+ in Adult Acute Myeloid Leukemia Patients.
- Authors
CUNHA DE PINHO PESSOA, FLÁVIA MELO; DIAS NOGUEIRA, BEATRIZ MARIA; BEZERRA MACHADO, CAIO; VALENTIM BARRETO, IGOR; DA COSTA MACHADO, ANNA KAROLYNA; BRITO GADELHA, RENAN; DE SOUSA OLIVEIRA, DEIVIDE; MONTEIRO RIBEIRO, RODRIGO; CARNEIRO SILVA, FABIANA AGUIAR; ANDRADE GURGEL, LÍVIA; COSTA MEDEIROS, JAIRA; DA ROCHA MACIEL, AURÉLIA; SILVA LOPES, GERMISON; GARCIA VIEIRA, RICARDO PARENTE; DE MORAES FILHO, MANOEL ODORICO; AMARAL DE MORAES, MARIA ELISABETE; SALIM KHAYAT, ANDRÉ; AQUINO MOREIRA-NUNES, CAROLINE
- Abstract
Background/Aim: Acute myeloid leukemia (AML) is a myeloproliferative neoplasm marked by abnormal clonal expansion of hematopoietic progenitor cells, displaying karyotypic aberrations and genetic mutations as prognostic indicators. The World Health Organization (WHO) and the European LeukemiaNet guidelines categorize BCR::ABL1 p190+ AML as high risk. This study explored the identification of the increased incidence of BCR::ABL1 p190+ in our AML population. Patients and Methods: This study included 96 AML patients stratified according to WHO guidelines. Subsequently, patients were screened for genetic abnormalities, such as BCR::ABL1 p 190+, PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11 by quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis. Results: Among 96 AML patients, 36 displayed BCR::ABL1 p190+, overcoming the expected global incidence. Age variations (19 to 78 years) showed no significant laboratory differences between BCR::ABL1 p190+ and non-BCR::ABL p190+ cases. The overall survival analysis revealed no statistically significant differences among the patients (p=0.786). Conclusion: The analyzed population presented a higher frequency of BCR::ABL1 p190+ detection in adult AML patients when compared to what is described in the worldwide literature. Therefore, more studies are needed to establish the reason why this incidence is higher and what the best treatment approach should be in these cases.
- Subjects
ACUTE myeloid leukemia diagnosis; PROGENITOR cells; GENE fusion; WORLD Health Organization; REVERSE transcriptase polymerase chain reaction
- Publication
In Vivo, 2024, Vol 38, Issue 4, p2016
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.13659